ScripHaving led calls for European countries to incentivize innovation by assigning higher value to medicines, Novartis CEO Vas Narasimhan has claimed that pharma companies would be less likely to launch t
ScripAt least officially, Bristol Myers Squibb and Pfizer’s are selling the anticlotting drug Eliquis (apixaban) directly to consumers to lower costs for patients, especially those who are uninsured, under
Pink SheetThe US Food and Drug Administration’s approval decisions for novel agents will come from different divisions in the second half of 2025, compared to the first half, the Pink Sheet ’s US FDA Performan
Pink SheetWith 22 novel agents approved in the first six months of 2025, the US FDA is already behind its average approval count for the first half of the year, and the user fee calendar for the second half doe